InSysBio announces its participation in An Introduction to QSP, A UK QSP Network hybrid (in person/online) event which is to be held 17-20hrs 24th October 2024. Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will discuss the prediction of the first-in-human dose for T-cell engagers using mechanistic modelling.
October 24, 18.15-18.50
Oleg Demin Jr comments on the topic, "While the minimal anticipated biological effect level (MABEL) PK-driven approach is recommended for determining the safe clinical starting dose for T-cell engagers (TCE), this method can sometimes yield a low minimal recommended starting dose (MRSD) resulting in treatment of patients with sub-therapeutic doses and multiple dose escalations. Quantitative Systems Pharmacology (QSP) modeling is another approach to predict MRSD for TCE with potentially higher predictive power. In my presentation, I will discuss the advantages and challenges of mechanistic modeling for the selection of MRSD and compare it with the MABEL PK-driven approach using a case study on HPN536, a TCE targeting mesothelin."
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
← | November 2018 | → | ||||
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1
|
2
|
3
|
4
| |||
5
|
6
1.
06 Nov 2018 17:27
Investigation of amyloid pathology mechanisms and prediction of clinical trial results using QSP model
InSysBio presents the video of Tatiana Karelina’s talk in framework of session “From translational PKPD models to quantitative system pharmacology in neurodegeneration drug development” at the 9th American Conference on Pharmacometrics (ACoP9):
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
26
1.
26 Nov 2018 14:03
InSysBio updates Immune Response Template online
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced a release of updated version of Immune Response Template (IRT) online. The main update in new 2.1.0 version is myeloid-derived suppressor cells (MDSCs). Published human in vitro and in vivo data were analyzed to reconstruct monocytic MDSCs (Mo-MDSCs) and granulocytic MDSCs (Gr-MDSCs) life cycles, derive equations and identify parameters.
|
27
|
28
|
29
|
30
|